• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Define Ventures Appoints Bruce Broussard as Venture Partner

    10/22/24 9:00:00 AM ET
    $EVH
    $HIMS
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $EVH alert in real time by email

    The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation

    SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companies. 

    Bruce is a seasoned healthcare executive and multi-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Bruce was president and CEO of Humana for over a dozen years. Under his leadership, Bruce led a strategic shift towards expanding the company into an integrated model with a growing care delivery focus. Bruce also held several roles at McKesson Specialty Health including CEO, CFO, President, and Chairman of the Board. He currently serves on the Humana Foundation Board, is Chair of the Board of Directors of the Trust for the National Mall, and is a board member for HP Inc. and One Call.

    "Bruce's extensive background and proven track record in leading healthcare organizations of all sizes makes him uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege to closely partner with Bruce for the past decade, I am confident his decision to join our team will sharpen our investing theses, accelerate our partner companies' growth, strengthen our relationships with large healthcare organizations, and ultimately create a lasting impact on the broader health tech community."

    Bruce is joining a team that pulls the full weight of its network and expertise to play offense and drive results, including securing early customers, shaping commercial strategies, and building high-performing teams. As venture partner, Bruce will leverage his experience driving transformative change within complex healthcare organizations to help Define founders to navigate industry challenges and scale their innovations effectively. His perspective will also strengthen Define's close partnerships with its coalition of large health systems, health plans, employers, and life sciences companies, half of which are customers of Define partner companies.

    "What excites me the most about this role is the opportunity to work with brilliant, innovative entrepreneurs at the earliest stages of their journey," Broussard said. "Being able to see groundbreaking approaches from the start, and having the chance to shape products and help scale and bring them to market is truly invigorating. Ultimately, I chose to work with Define because I believe this firm is uniquely positioned and capable of driving real transformation in healthcare. The strong, trustworthy relationship we've built over the years has shown me that Define's vision aligns perfectly with my own. Together, I believe we can make significant strides in creating a healthcare system that's more efficient, more accessible, and more focused on keeping people healthy."

    Bruce's decision to join Define Ventures stems from his belief that the firm is uniquely positioned and capable of transforming healthcare. He has built a strong and trustworthy relationship with Define over the past several years, including first-hand experience in incubating and spinning out Cohere Health from Humana. This collaborative history underscores the alignment between Bruce's vision for healthcare innovation and Define's strategic approach.

    Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm attracts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE:HIMS) and Unite Us. This announcement follows Frank Williams, co-founder and former CEO of Evolent (NYSE:EVH) joining Define as venture partner earlier this year.

    To learn more about Define Ventures, visit www.definevc.com.

    About Define Ventures

    Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 AUM, we take a high conviction approach in partnering with companies at the earliest stages. We believe the future of healthcare will be defined who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built in this vision, bringing together founders and investors who built category-defining companies and delivered $23 billion in exit value, including Livongo (LVGO), Evolent (NYSE:EVH), and Hims & Hers (NYSE:HIMS).

    Cision View original content:https://www.prnewswire.com/news-releases/define-ventures-appoints-bruce-broussard-as-venture-partner-302282546.html

    SOURCE Define Ventures

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has joined Define Ventures as a venture partner, and what is his background?

      Bruce Broussard, the former CEO of Humana, has joined Define Ventures as a venture partner to drive transformative change in healthcare and support early-stage health tech companies.

    • What is Define Ventures' focus and how much capital do they manage?

      Define Ventures focuses on early-stage health tech companies and has $800 million in assets under management (AUM). They partner with companies typically at the seed, series A, and series B stages.

    • Why has Bruce Broussard chosen to work with Define Ventures?

      Broussard believes Define Ventures is uniquely positioned to drive real transformation in healthcare, based on his strong relationship with the firm and shared vision for healthcare innovation.

    • What role will Bruce Broussard play at Define Ventures?

      Broussard will leverage his extensive experience in healthcare to guide founders through challenges, helping them scale their innovations and strengthen partnerships with large healthcare organizations.

    • Which companies has Define Ventures partnered with, showcasing their investment strategy?

      Define Ventures has partnered with notable companies in the health tech space, including Hims & Hers and Unite Us, highlighting their investment strategy focused on impactful entrepreneurs.

    Recent Analyst Ratings for
    $EVH
    $HIMS
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    Humana Inc.
    $HUM
    12/5/2025$313.00Hold → Buy
    Jefferies
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Outperform
    BMO Capital Markets
    Hims & Hers Health Inc.
    $HIMS
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    Humana Inc.
    $HUM
    10/14/2025$235.00Sell
    Goldman
    Humana Inc.
    $HUM
    9/22/2025$295.00In-line
    Evercore ISI
    Hims & Hers Health Inc.
    $HIMS
    6/23/2025Buy → Hold
    Needham
    More analyst ratings

    $EVH
    $HIMS
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana upgraded by Jefferies with a new price target

    Jefferies upgraded Humana from Hold to Buy and set a new price target of $313.00

    12/5/25 8:31:42 AM ET
    $HUM
    Medical Specialities
    Health Care

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humana, Nurses on Boards Coalition Announce New Partnership to Mentor Emerging Nurses

    Humana has announced a new partnership with the national Nurses on Boards Coalition (NOBC) to provide mentors for nursing students. Humana is providing a gift of $110,000 for first-year funding to support the NOBC's Mentoring for Success program, which will match 50 nursing students with 50 mentors who work as nurses for Humana. The mentoring program gets underway in early 2026. Humana would then continue funding the program at $90,000 per year after that. With its gift, Humana becomes a founding partner of the mentoring initiative and now has a leadership seat on the program's advisory board impact group. "Humana employs more than 10,000 nurses, including many in our CenterWell health c

    12/17/25 11:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    AM Best Affirms Credit Ratings of Humana Inc. and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) for the health and dental insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) (NYSE:HUM). These subsidiaries collectively are referred to as Humana Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb" (Good) and the Long-Term Issue Credit Ratings (Long-Term IRs) of Humana Inc. (Humana). AM Best also has affirmed the Short-Term Issue Credit Rating of AMB-2 (Satisfactory) for Humana. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of Humana Health Group

    12/16/25 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Carroll Patrick Harrison sold $367,871 worth of shares (10,021 units at $36.71), decreasing direct ownership by 6% to 169,940 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    12/18/25 4:15:36 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Policy Officer Autor Deborah M. sold $258,952 worth of shares (7,054 units at $36.71), decreasing direct ownership by 53% to 6,175 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    12/18/25 4:15:42 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Operating Officer Chi Michael sold $504,762 worth of shares (13,750 units at $36.71), decreasing direct ownership by 4% to 305,161 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    12/18/25 4:15:48 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    SEC Filings

    View All

    SEC Form S-8 POS filed by Humana Inc.

    S-8 POS - HUMANA INC (0000049071) (Filer)

    12/19/25 4:57:12 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    12/16/25 8:05:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Evolent Health Inc filed SEC Form 8-K: Other Events

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    12/8/25 8:00:06 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of Humana Inc. and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) for the health and dental insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) (NYSE:HUM). These subsidiaries collectively are referred to as Humana Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb" (Good) and the Long-Term Issue Credit Ratings (Long-Term IRs) of Humana Inc. (Humana). AM Best also has affirmed the Short-Term Issue Credit Rating of AMB-2 (Satisfactory) for Humana. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of Humana Health Group

    12/16/25 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance

    Reports 3Q25 earnings per share (EPS) of $1.62 on a GAAP basis, Adjusted EPS of $3.24; reports YTD EPS of $16.43 on a GAAP basis, $21.10 on an Adjusted basis 3Q25 Insurance segment benefit ratio of 91.1 percent, in line with the company's previously disclosed expectation of 'just above 91 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $12.26' from the previous estimate of 'approximately $13.77'; affirms Adjusted FY 2025 EPS guidance of 'approximately $17.00' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Updates FY 2025 individual Medicare Advantage membership guidance to now anticipate a decline of 'approximately 425,00

    11/5/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care